Literature DB >> 9083889

A novel human monoclonal antibody rapidly induces homotypic cell aggregation and promotes antibody-secreting activity by human B lymphoblastoid cell line IM-9.

N Ikewaki1.   

Abstract

A human monoclonal antibody (mAb), designated mNKES, was generated by fusing B cells isolated from an enlarged cervical lymph node of a patient with a carotid body tumor (CBT), with human myeloma cell line KR-12 (6TG). The reactivity of mNKES was tested by the indirect immunofluorescence method. The antigen defined by mNKES was expressed on Burkitt's lymphoma cell lines Raji, Daudi, and Ramos and on B lymphoblastoid cell line IM-9. In addition, mNKES reacted with T cells stimulated with recombinant interleukin-2 (rIL-2) obtained from normal healthy donors. However, mNKES did not react with normal resting human T, B, or adherent cells (monocytes/macrophages). When the reactivity of mNKES and mouse mAbs recognizing the human adhesion-associated antigen (CD10, CD11a, CD11b, CD11c, CD14, CD16, CD18, CD23, CD28, CD29, CD31, CD43, CD44, CD45RA, CD50, CD54, CD58, CD80, CD102, CD106, and HLA class I, and HLA class II antigen) with various cell lines was compared, mNKES reactivity was found to be unique, not resembling that of any of these mouse mAbs. Interestingly, mNKES specifically and rapidly (within 2 hr) induced homotypic cell aggregation of IM-9 cells. This mNKES-induced cell aggregation was completely blocked by the addition of EDTA and when incubated at 4 degrees C. The mAbs reactive with CD11a/CD18 (leukocyte function-associated antigen-1; LFA-1) and CD54 (intercellular adhesion molecule-1; ICAM-1) completely blocked the IM-9 cell aggregation induced by mNKES, and induction of IM-9 cell aggregation by mNKES was significantly blocked in the presence of the protein kinase C inhibitors sphingosine and H-7 and completely blocked by cytochalasin B and cytochalasin D, which inhibit microfilament formation. Regarding biological function, IM-9 cells bearing surface IgG (sIgG) effectively promoted IgG-secreting activity underlying the homotypic cell aggregation induced by mNKES. The surface antigen recognized by mNKES has a molecular size of about 55 kDa, as determined by immunoblotting analysis. These findings indicate that mNKES recognizes a novel adhesion-associated antigen distinct from any previously reported adhesion-associated antigens in terms of pattern of cellular distribution and biological function and that mNKES is the first human mAb found that rapidly induces homotypic cell aggregation and effectively promotes the IgG-secreting activity of human B lymphoblastoid cell line IM-9.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9083889     DOI: 10.1023/a:1027374331094

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  51 in total

1.  Differential expression of LFA-1 molecules in non-Hodgkin's lymphoma and lymphoid leukemia.

Authors:  G Inghirami; R Wieczorek; B Y Zhu; R Silber; R Dalla-Favera; D M Knowles
Journal:  Blood       Date:  1988-10       Impact factor: 22.113

2.  Identification of a novel adhesion molecule in human leukocytes by monoclonal antibody LB-2.

Authors:  M Patarroyo; E A Clark; J Prieto; C Kantor; C G Gahmberg
Journal:  FEBS Lett       Date:  1987-01-05       Impact factor: 4.124

3.  CD23 and CD21 function as adhesion molecules in homotypic aggregation of human B lymphocytes.

Authors:  P Björck; C Elenström-Magnusson; A Rosén; E Severinson; S Paulie
Journal:  Eur J Immunol       Date:  1993-08       Impact factor: 5.532

4.  Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development.

Authors:  M R Loken; V O Shah; K L Dattilio; C I Civin
Journal:  Blood       Date:  1987-11       Impact factor: 22.113

5.  Involvement of a leukocyte adhesion receptor (LFA-1) in HIV-induced syncytium formation.

Authors:  J E Hildreth; R J Orentas
Journal:  Science       Date:  1989-06-02       Impact factor: 47.728

6.  CD45 mAb induces cell adhesion in peripheral blood mononuclear cells via lymphocyte function-associated antigen-1 (LFA-1) and intercellular cell adhesion molecule 1 (ICAM-1).

Authors:  H M Lorenz; T Harrer; A S Lagoo; A Baur; G Eger; J R Kalden
Journal:  Cell Immunol       Date:  1993-03       Impact factor: 4.868

7.  Antibody against the Leu-CAM beta-chain (CD18) promotes both LFA-1- and CR3-dependent adhesion events.

Authors:  M K Robinson; D Andrew; H Rosen; D Brown; S Ortlepp; P Stephens; E C Butcher
Journal:  J Immunol       Date:  1992-02-15       Impact factor: 5.422

8.  Development and characterization of a human monoclonal antibody probably detecting the leukocyte differentiation antigen CD39.

Authors:  N Ikewaki; S Takabe; K Tsuji
Journal:  Tissue Antigens       Date:  1992-04

9.  Monoclonal antibody (H107) inhibiting IgE binding to Fc epsilon R(+) human lymphocytes.

Authors:  N Noro; A Yoshioka; M Adachi; K Yasuda; T Masuda; J Yodoi
Journal:  J Immunol       Date:  1986-08-15       Impact factor: 5.422

10.  Intercellular adhesion molecule 3, a third adhesion counter-receptor for lymphocyte function-associated molecule 1 on resting lymphocytes.

Authors:  A R de Fougerolles; T A Springer
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

View more
  3 in total

1.  A microfilament formation inhibitor, cytochalasin strongly enhances the low-affinity Fc epsilon receptor II (CD23) expression on the human monocyte-like cell line, U937.

Authors:  N Ikewaki; H Tamauchi; A Yamada; M Aoki; R Yamamoto; A Sawada; H Inoko
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

2.  A unique monoclonal antibody mNI-11 rapidly enhances spread formation in human umbilical vein endothelial cells.

Authors:  N Ikewaki; H Tamauchi; A Yamada; N Mori; H Yamao; H Inoue; H Inoko
Journal:  J Clin Immunol       Date:  2000-07       Impact factor: 8.317

3.  CD13 in cell adhesion: aminopeptidase N (CD13) mediates homotypic aggregation of monocytic cells.

Authors:  Paola Mina-Osorio; Linda H Shapiro; Enrique Ortega
Journal:  J Leukoc Biol       Date:  2006-01-13       Impact factor: 4.962

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.